Neurotech Solutions

Neurotech Solutions Overview

Neurotech solutions is a digital health company focused on eliminating undiagnosed ADHD. The companys mission is to help every person with ADHD lead a better life and fulfill their potential. Neurotech Solutions core technology is a cloud-based, AI-driven online test that looks and feels like a game. The technology was first implemented in a clinical product called MOXO d-CPT, a decision-support tool for the diagnosis of ADHD. Using MOXO d-CPT, a healthcare professional can obtain objective, standardized, comparative results about a patients attentional difficulties in just 14 to 18 minutes. More than 500,000 MOXO tests have been performed to date in over 20 countries. During the COVID-19 pandemic, the company released a home version of MOXO to enable a full remote and objective diagnosis of ADHD. The companys core technology was also implemented in an educational product called AXON-School. Intended for all K-12 children, the product objectively highlights children with attentional difficulties and suggests educational strategies for personalized learning. Neurotech Solutions opened a subsidiary in Guangzhou, China, in 2021.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 9, 2020 · cordis.europa.eu

Mobile device for ADHD diagnosis and support MOXO-Mobile Phase-1 Project Results in brief H2020 CORDIS European Commission

Mar 14, 2018 · www.linkedin.com

growth-positive

Neurotech-Solutions Secures $3.5 Million to Fuel Aggressive Growth of its ADHD screening and diagnosis business in China.

Neurotech Solutions, a leading provider of software-based ADHD screening and diagnostic tests, has secured a $3.5 million investment for sales growth in China. The investment will enable the company to expand into the Chinese market and tap into a $1 billion market opportunity. The investment was led by the Guangzhou-Israel Biotech Fund, financially supported by the local government of Guangzhou city. Neurotech Solutions aims to build a unique ecosystem in China to advance the quality of ADHD diagnosis and treatment. The company predicts reaching $75 million in sales within 3 years. ADHD is a common neurodevelopmental disorder in China, and Neurotechs AI-based system offers a more accurate and efficient solution compared to subjective questionnaires.

InvestmentPartners

Jun 18, 2015 · www.israel21c.org

growth-positive

Customizing ADHD evaluation

Nes Ziona-based NeuroTechnology Solutions has developed Moxo Analytics, an Internet-based software technology that helps clinicians diagnose and monitor attention-deficit/hyperactivity disorder (ADHD). Moxo has different versions for children and adults and provides scores on various components of ADHD. The system has already received the European Unions CE mark and is being used in several countries. The worldwide prevalence of ADHD is between 5.29 and 7.1 percent in people under 18 years old. NeuroTechnology Solutions aims to enhance the clinicians assessment and treatment process with Moxo.

Customers

Funding

Team Members

6

Employees: 11-50

Web & Social Links

Locations

Pinkas Street 66, Tel Aviv-Yafo, Israel

Guangzhou, Guangdong, China

Photos & Videos

3 item(s)

Neurotech Solutions Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info